Skip to content Skip to footer
Subscribe Now
Viewpoints_Mina Makar
VIEWPOINTS

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots:  Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032.  The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD.  In collaboration with…
October 28, 2024

Read more

Viewpoints_Dr. Robert Rifikin
VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States  Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity   Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
August 5, 2024

Read more

Innovative Digital Therapeutics Top 20 2024
TOP 20

Top 20 Innovative Digital Therapeutics Companies of 2024

Shots: New-age technologies are transforming the healthcare industry continuously. By leveraging digital health platforms, AI-powered apps, and other innovative solutions, there is a significant enhancement in diagnosis, treatment, and prevention With a global market revenue of $180.2B in 2023, the market is projected to reach $549.7B by 2028, registering a CAGR of 25 percent. This…
June 27, 2024

Read more

INSIGHTS+

Disease of the Month – Fabry Disease

Shots:  Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components  In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…
June 12, 2024

Read more

Disease of the Month – Sjögren’s Syndrome
INSIGHTS+

Disease of the Month – Sjögren’s Syndrome

Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024

Read more

VIEWPOINTS_Richard Stefanacci_2024
VIEWPOINTS

Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots

Shots:  Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment  While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024

Read more

Disease of the Month - Alport Syndrome
INSIGHTS+

Disease of the Month – Alport Syndrome

Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research  In the next installment to our disease report, this month we have covered a detailed analysis of Alport Syndrome, which is a rare genetic disorder…
March 11, 2024

Read more

VIEWPOINTS_Philip M. Brown1_G. Michael Lewitt2_2024
VIEWPOINTS

Treating Plaque Psoriasis with VTAMA: Dermavant ‘s Philip M. Brown & G. Michael Lewitt in Conversation with PharmaShots

Shots:  G. Michael Lewitt and Philip M.Brown enlightened PharmaShots’ audience on Dermavant Sciences’ VTAMA cream a first-in-its-class topical prescription medication approved for Plaque Psoriasis  Michael & Philip discussed VTAMA’s study design along with its MOA, ROA, and formulation while shedding light on P-IV data  Philip further goes ahead to share details on VTAMA’s ongoing study…
February 29, 2024

Read more

Load more